Cargando…

Expanding anti-CD38 immunotherapy for lymphoid malignancies

BACKGROUND: Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xu, Yu, Xinfang, Li, Wei, Neeli, Praveen, Liu, Ming, Li, Ling, Zhang, Mingzhi, Fang, Xiaosheng, Young, Ken H., Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237984/ https://www.ncbi.nlm.nih.gov/pubmed/35765110 http://dx.doi.org/10.1186/s13046-022-02421-2

Ejemplares similares

AI-powered discovery of a novel p53-Y220C reactivator
por: Zhou, Shan, et al.
Publicado: (2023)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

P1378: CAR-T CELLS TARGETING CD38 AND LMP1 EXHIBIT ROBUST ANTI-TUMOR ACTIVITY AGAINST NK/T-CELL LYMPHOMA
por: Hongwen, LI, et al.
Publicado: (2023)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

CD20(+)CD22(+)ADAM28(+) B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response
por: Wu, Zhenghao, et al.
Publicado: (2022)

EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOID MALIGNANCIES: THE EXPANDING SPECTRUM OF HEMATOPOIETIC NEOPLASMS
por: KIMURA, HIROSHI, et al.
Publicado: (2013)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

CD38-NAD(+)-Sirt1 axis in T cell immunotherapy
por: Chatterjee, Shilpak, et al.
Publicado: (2019)

Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
por: Gambles, M. Tommy, et al.
Publicado: (2021)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

CD127+ CD94+ innate lymphoid cells expressing granulysin and perforin are expanded in patients with Crohn’s disease
por: Krabbendam, L., et al.
Publicado: (2021)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
por: Sun, Rui-Fang, et al.
Publicado: (2018)

It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies
por: Besson, Caroline
Publicado: (2021)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Lymphoid malignancies ARNT unstoppable
por: Gardella, Kacie A., et al.
Publicado: (2016)

Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy
por: Allegra, Alessandro, et al.
Publicado: (2022)

Tertiary Lymphoid Structures as Mediators of Immunotherapy Response
por: Vaghjiani, Raj G., et al.
Publicado: (2022)

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response
por: Dalgleish, A, et al.
Publicado: (2014)

Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation
por: Li, Yixin, et al.
Publicado: (2010)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Beyond NK Cells: The Expanding Universe of Innate Lymphoid Cells
por: Cella, Marina, et al.
Publicado: (2014)

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
por: Shang, Taiyu, et al.
Publicado: (2023)

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
por: Grandclement, C., et al.
Publicado: (2022)

Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
por: Neeli, Praveen, et al.
Publicado: (2023)

Development of venetoclax for therapy of lymphoid malignancies
por: Zhu, Huayuan, et al.
Publicado: (2017)

Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021)

Effects of COVID-19 in lymphoid malignancies
por: Özdemir, Öner
Publicado: (2021)

Targeting PD-L1 in non-small cell lung cancer using CAR T cells
por: Liu, Ming, et al.
Publicado: (2020)

COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
por: Ito, Yusuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_igrlf4a3afpkiv13srbhh1ratl